Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer
CapeOX is a regimen used as postoperative adjuvant chemotherapy for the treatment of advanced recurrent colorectal cancer. If early adverse events occur, treatment may not progress as planned and further dose reduction may be necessary. In this study, we investigated whether pre-treatment medical re...
Gespeichert in:
| Veröffentlicht in: | The Journal of Medical Investigation 2024, Vol.71(1.2), pp.141-147 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 147 |
|---|---|
| container_issue | 1.2 |
| container_start_page | 141 |
| container_title | The Journal of Medical Investigation |
| container_volume | 71 |
| creator | Kumihashi, Yuki Kasai, Yohei Akagawa, Takuya Yuasa, Yasuhiro Ishikura, Hisashi Sato, Youichi |
| description | CapeOX is a regimen used as postoperative adjuvant chemotherapy for the treatment of advanced recurrent colorectal cancer. If early adverse events occur, treatment may not progress as planned and further dose reduction may be necessary. In this study, we investigated whether pre-treatment medical records could be used to predict adverse events in order to prevent adverse events caused by CapeOX treatment. The 178 patients were classified into two groups (97 in the adverse event positive group and 81 in the adverse event-negative group) based on withdrawal or postponement of four or fewer courses. In univariate analysis, age, height, weight, body surface area (BSA), creatinine clearance, muscle mass, and lean body mass were associated with early adverse events (P |
| doi_str_mv | 10.2152/jmi.71.141 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2152_jmi_71_141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38735710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-24bc497aeb18666fe6bfe598e234d9048b5a0f0eaecd14bf2e34aee1654f1b5d3</originalsourceid><addsrcrecordid>eNo9kM9LwzAYhoMobk4v_gGSs9CZNEnbnUSGv2CwgwreYpJ-cRldW5Js0v_eus2evhfe53sPD0LXlExTKtK79cZNczqlnJ6gMWV8lmRFlp_uM0soT8kIXYSwJoQxIcQ5GrEiZyKnZIy-3uK27HBT49ZD6Ux0fWwsBuWrDqtyBz4Ahh3UMWDd4blqYfmJ4wq8ajvs-j8V3b79cXGFTVM1HkxUFTaqNuAv0ZlVVYCr452gj6fH9_lLslg-v84fFonhhMck5drwWa5A0yLLMguZtiBmBaSMlzPCCy0UsQQUmJJybVNgXAHQTHBLtSjZBN0edo1vQvBgZevdRvlOUiL_NMlek8yp7DX18M0Bbrd6A-WA_nvpgfsDsA5RfcMAKB-dqWDYkulxcmjMSnkJNfsFEjR8Dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Freely Accessible Japanese Titles</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kumihashi, Yuki ; Kasai, Yohei ; Akagawa, Takuya ; Yuasa, Yasuhiro ; Ishikura, Hisashi ; Sato, Youichi</creator><creatorcontrib>Kumihashi, Yuki ; Kasai, Yohei ; Akagawa, Takuya ; Yuasa, Yasuhiro ; Ishikura, Hisashi ; Sato, Youichi</creatorcontrib><description>CapeOX is a regimen used as postoperative adjuvant chemotherapy for the treatment of advanced recurrent colorectal cancer. If early adverse events occur, treatment may not progress as planned and further dose reduction may be necessary. In this study, we investigated whether pre-treatment medical records could be used to predict adverse events in order to prevent adverse events caused by CapeOX treatment. The 178 patients were classified into two groups (97 in the adverse event positive group and 81 in the adverse event-negative group) based on withdrawal or postponement of four or fewer courses. In univariate analysis, age, height, weight, body surface area (BSA), creatinine clearance, muscle mass, and lean body mass were associated with early adverse events (P<0.05). The area under the receiver operating characteristic curve obtained by Stepwise logistic regression analysis using the Akaike information criterion method was 0.832. For nested k-fold cross validation, the accuracy rates of the support vector machine, random forest, and logistic regression algorithms were 0.71, 0.70, and 0.75, respectively. The results of the present study suggest that a logistic regression prediction model may be useful in predicting early adverse events caused by CapeOX therapy in patients with colorectal cancer. J. Med. Invest. 71 : 141-147, February, 2024</description><identifier>ISSN: 1343-1420</identifier><identifier>EISSN: 1349-6867</identifier><identifier>DOI: 10.2152/jmi.71.141</identifier><identifier>PMID: 38735710</identifier><language>eng</language><publisher>Japan: The University of Tokushima Faculty of Medicine</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Capecitabine - administration & dosage ; Capecitabine - adverse effects ; CapeOX ; Colorectal Neoplasms - drug therapy ; early adverse events ; Female ; Humans ; Male ; Middle Aged ; multivariate logistic regression ; nested k-fold cross validation ; prediction ; Retrospective Studies</subject><ispartof>The Journal of Medical Investigation, 2024, Vol.71(1.2), pp.141-147</ispartof><rights>2024 by The University of Tokushima Faculty of Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c404t-24bc497aeb18666fe6bfe598e234d9048b5a0f0eaecd14bf2e34aee1654f1b5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1876,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38735710$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumihashi, Yuki</creatorcontrib><creatorcontrib>Kasai, Yohei</creatorcontrib><creatorcontrib>Akagawa, Takuya</creatorcontrib><creatorcontrib>Yuasa, Yasuhiro</creatorcontrib><creatorcontrib>Ishikura, Hisashi</creatorcontrib><creatorcontrib>Sato, Youichi</creatorcontrib><title>Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer</title><title>The Journal of Medical Investigation</title><addtitle>J. Med. Invest.</addtitle><description>CapeOX is a regimen used as postoperative adjuvant chemotherapy for the treatment of advanced recurrent colorectal cancer. If early adverse events occur, treatment may not progress as planned and further dose reduction may be necessary. In this study, we investigated whether pre-treatment medical records could be used to predict adverse events in order to prevent adverse events caused by CapeOX treatment. The 178 patients were classified into two groups (97 in the adverse event positive group and 81 in the adverse event-negative group) based on withdrawal or postponement of four or fewer courses. In univariate analysis, age, height, weight, body surface area (BSA), creatinine clearance, muscle mass, and lean body mass were associated with early adverse events (P<0.05). The area under the receiver operating characteristic curve obtained by Stepwise logistic regression analysis using the Akaike information criterion method was 0.832. For nested k-fold cross validation, the accuracy rates of the support vector machine, random forest, and logistic regression algorithms were 0.71, 0.70, and 0.75, respectively. The results of the present study suggest that a logistic regression prediction model may be useful in predicting early adverse events caused by CapeOX therapy in patients with colorectal cancer. J. Med. Invest. 71 : 141-147, February, 2024</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Capecitabine - administration & dosage</subject><subject>Capecitabine - adverse effects</subject><subject>CapeOX</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>early adverse events</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multivariate logistic regression</subject><subject>nested k-fold cross validation</subject><subject>prediction</subject><subject>Retrospective Studies</subject><issn>1343-1420</issn><issn>1349-6867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM9LwzAYhoMobk4v_gGSs9CZNEnbnUSGv2CwgwreYpJ-cRldW5Js0v_eus2evhfe53sPD0LXlExTKtK79cZNczqlnJ6gMWV8lmRFlp_uM0soT8kIXYSwJoQxIcQ5GrEiZyKnZIy-3uK27HBT49ZD6Ux0fWwsBuWrDqtyBz4Ahh3UMWDd4blqYfmJ4wq8ajvs-j8V3b79cXGFTVM1HkxUFTaqNuAv0ZlVVYCr452gj6fH9_lLslg-v84fFonhhMck5drwWa5A0yLLMguZtiBmBaSMlzPCCy0UsQQUmJJybVNgXAHQTHBLtSjZBN0edo1vQvBgZevdRvlOUiL_NMlek8yp7DX18M0Bbrd6A-WA_nvpgfsDsA5RfcMAKB-dqWDYkulxcmjMSnkJNfsFEjR8Dw</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Kumihashi, Yuki</creator><creator>Kasai, Yohei</creator><creator>Akagawa, Takuya</creator><creator>Yuasa, Yasuhiro</creator><creator>Ishikura, Hisashi</creator><creator>Sato, Youichi</creator><general>The University of Tokushima Faculty of Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2024</creationdate><title>Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer</title><author>Kumihashi, Yuki ; Kasai, Yohei ; Akagawa, Takuya ; Yuasa, Yasuhiro ; Ishikura, Hisashi ; Sato, Youichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-24bc497aeb18666fe6bfe598e234d9048b5a0f0eaecd14bf2e34aee1654f1b5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Capecitabine - administration & dosage</topic><topic>Capecitabine - adverse effects</topic><topic>CapeOX</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>early adverse events</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multivariate logistic regression</topic><topic>nested k-fold cross validation</topic><topic>prediction</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumihashi, Yuki</creatorcontrib><creatorcontrib>Kasai, Yohei</creatorcontrib><creatorcontrib>Akagawa, Takuya</creatorcontrib><creatorcontrib>Yuasa, Yasuhiro</creatorcontrib><creatorcontrib>Ishikura, Hisashi</creatorcontrib><creatorcontrib>Sato, Youichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Journal of Medical Investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumihashi, Yuki</au><au>Kasai, Yohei</au><au>Akagawa, Takuya</au><au>Yuasa, Yasuhiro</au><au>Ishikura, Hisashi</au><au>Sato, Youichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer</atitle><jtitle>The Journal of Medical Investigation</jtitle><addtitle>J. Med. Invest.</addtitle><date>2024</date><risdate>2024</risdate><volume>71</volume><issue>1.2</issue><spage>141</spage><epage>147</epage><pages>141-147</pages><issn>1343-1420</issn><eissn>1349-6867</eissn><abstract>CapeOX is a regimen used as postoperative adjuvant chemotherapy for the treatment of advanced recurrent colorectal cancer. If early adverse events occur, treatment may not progress as planned and further dose reduction may be necessary. In this study, we investigated whether pre-treatment medical records could be used to predict adverse events in order to prevent adverse events caused by CapeOX treatment. The 178 patients were classified into two groups (97 in the adverse event positive group and 81 in the adverse event-negative group) based on withdrawal or postponement of four or fewer courses. In univariate analysis, age, height, weight, body surface area (BSA), creatinine clearance, muscle mass, and lean body mass were associated with early adverse events (P<0.05). The area under the receiver operating characteristic curve obtained by Stepwise logistic regression analysis using the Akaike information criterion method was 0.832. For nested k-fold cross validation, the accuracy rates of the support vector machine, random forest, and logistic regression algorithms were 0.71, 0.70, and 0.75, respectively. The results of the present study suggest that a logistic regression prediction model may be useful in predicting early adverse events caused by CapeOX therapy in patients with colorectal cancer. J. Med. Invest. 71 : 141-147, February, 2024</abstract><cop>Japan</cop><pub>The University of Tokushima Faculty of Medicine</pub><pmid>38735710</pmid><doi>10.2152/jmi.71.141</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1343-1420 |
| ispartof | The Journal of Medical Investigation, 2024, Vol.71(1.2), pp.141-147 |
| issn | 1343-1420 1349-6867 |
| language | eng |
| recordid | cdi_crossref_primary_10_2152_jmi_71_141 |
| source | J-STAGE Free; MEDLINE; Freely Accessible Japanese Titles; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Capecitabine - administration & dosage Capecitabine - adverse effects CapeOX Colorectal Neoplasms - drug therapy early adverse events Female Humans Male Middle Aged multivariate logistic regression nested k-fold cross validation prediction Retrospective Studies |
| title | Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A11%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Study%20on%20prediction%20of%20early%20adverse%20events%20by%20CapeOX%20therapy%20in%20patients%20with%20colorectal%20cancer&rft.jtitle=The%20Journal%20of%20Medical%20Investigation&rft.au=Kumihashi,%20Yuki&rft.date=2024&rft.volume=71&rft.issue=1.2&rft.spage=141&rft.epage=147&rft.pages=141-147&rft.issn=1343-1420&rft.eissn=1349-6867&rft_id=info:doi/10.2152/jmi.71.141&rft_dat=%3Cpubmed_cross%3E38735710%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38735710&rfr_iscdi=true |